SCHEMBL3009908

SCHEMBL3009908

O=S(=O)(c1cc(Cl)cc(Cl)c1)C1CCN(c2nc(Cc3ccc(Cl)c(Cl)c3)cs2)CC1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
AR P10275 2/20 0.38
MAPT P10636 1/20 0.36
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
RAB9A P51151 1/20 0.34
SLC13A5 Q86YT5 2/20 0.33
SPR P35270 1/20 0.33
HTR2A P28223 1/20 0.33
ERBB2 P04626 1/20 0.33
EPHA2 P29317 1/20 0.33
HRH3 Q9Y5N1 1/20 0.32
FPR2 P25090 1/20 0.32
PROKR1 Q8TCW9 1/20 0.32
HTR6 P50406 1/20 0.32
AOC3 Q16853 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017923 0.93 MAPT (0.40) LMNAL3MBTL1ARMAPTGAA
SCHEMBL3013801 0.93 L3MBTL1 (0.39) LMNAL3MBTL1ARMAPTGAA
SCHEMBL3001750 0.92 RAB9A (0.39) LMNAL3MBTL1ARMAPTGAA
SCHEMBL3017605 0.92 MAPT (0.35) LMNAL3MBTL1ARMAPTGAA
SCHEMBL3015894 0.91 MAPT (0.35) LMNAL3MBTL1MAPTGAASMN1; SMN2
SCHEMBL3016582 0.91 MAPT (0.40) LMNAMAPTGAASMN1; SMN2RAB9A
SCHEMBL3019243 0.90 L3MBTL1 (0.38) LMNAL3MBTL1ARMAPTGAA
SCHEMBL3016860 0.90 L3MBTL1 (0.36) LMNAL3MBTL1ARMAPTGAA
SCHEMBL3011357 0.90 L3MBTL1 (0.36) LMNAL3MBTL1ARMAPTGAA
SCHEMBL3021485 0.90 MAPT (0.35) LMNAL3MBTL1MAPTGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885L3MBTL1 1847/4885AR 3801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.